

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8324100

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
AEQUUS PHARMACEUTICALS, INC.	12/11/2023
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	TRANSDERMAL RESEARCH PHARM LABORATORIES, LLC
<b>Street Address:</b>	157-14 CRYDERS LANE
<b>City:</b>	WHITESTONE
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	11357
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	10500196
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	patents@potomaclaw.com, aarmstrong@potomaclaw.com
<b>Correspondent Name:</b>	ALICIA ARMSTRONG
<b>Address Line 1:</b>	1717 PENNSYLVANIA AVENUE NW
<b>Address Line 2:</b>	SUITE 1025
<b>Address Line 4:</b>	WASHINGTON, D.C. 20006
<b>ATTORNEY DOCKET NUMBER:</b>	4783-0056US01
<b>NAME OF SUBMITTER:</b>	ALICIA ARMSTRONG
<b>SIGNATURE:</b>	/Alicia Armstrong/
<b>DATE SIGNED:</b>	12/12/2023
<b>Total Attachments: 3</b>	
source=4783-0056US01_Assignment_signed#page1.tif	
source=4783-0056US01_Assignment_signed#page2.tif	
source=4783-0056US01_Assignment_signed#page3.tif	

## ASSIGNMENT OF INVENTION

WHEREAS, AEQUUS PHARMACEUTICALS, Inc., a company organized and existing under the laws of British Columbia and having a business address of 2820 – 200 Granville Street, Vancouver, BC, Canada, V6C 1S4 (“ASSIGNOR”) owns all right, title and interest in and to the patents and/or patent applications identified in Schedule A attached hereto (collectively the “Patents”); and

WHEREAS, TRANSDERMAL RESEARCH PHARM LABORATORIES, LLC, a company organized and existing under the laws of the State of New York and having an office and place of business at 157 – 14 Cryders Lane, Whitestone NY 11357 (“ASSIGNEE”) is desirous of acquiring the entire right, title and interest of ASSIGNOR in and to the Patents, and the entire right, title and interest that are acquired by ASSIGNOR, in and throughout the United States, its territories and all countries foreign thereto, and in and to the Patents, and any utility Applications for United States Letters Patent based in whole or in part upon the Patents and in and to any and all Letters Patent of the United States and all countries foreign thereto which have been granted or may be granted on the Patents or any part thereof;


NOW, THEREFORE, for the sum of one dollar (\$1) and other good and valuable consideration, the sufficiency of which is acknowledged, ASSIGNOR, agrees to assign and transfer and does hereby assign and transfer unto said ASSIGNEE, the entire right, title and interest of ASSIGNOR in and to the Patents, and the entire right, title and interest in and throughout the United States, its territories and all countries foreign thereto, and in and to the Patents, and any utility, divisional, continuing, continuation-in-part, renewal, or reissue applications for United States Letters Patent based in whole or in part upon the Patents and any foreign applications based in whole or in part upon the Patents and in and to any and all Letters Patent of the United States and all countries foreign thereto which have been granted or may be granted on said applications or any part thereof, and in and to and similar protective rights granted on said foreign applications, and in and to the right to claim any applicable priority rights arising from or required for said foreign applications under the terms of any applicable conventions, treaties, statutes, or regulations, said foreign applications to be filed and issued in the name of ASSIGNEE, or its designee insofar as permitted by applicable law.

ASSIGNOR further agrees that all necessary records of ASSIGNOR to establish priority of invention in any interference or similar proceeding will be made available at no additional charge to ASSIGNEE in the event such records are needed in connection with the assigned Applications.



ASSIGNOR hereby requests the Commissioner of Patents and Trademarks to issue any and all Letters Patent of the United States resulting in whole or in part from the Patents, or from any utility, divisional, continuing, continuation-in-part, renewal or reissue application thereof, to ASSIGNEE, as the assignee, for its interests and for the sole use and benefit of ASSIGNEE and its assignees, legal representatives or other designees.

IN WITNESS WHEREOF, the undersigned has caused this Assignment to be executed by its duly authorized officer, on this 11 day of DECEMBER 2023.

AEQUUS PHARMACEUTICALS, Inc.

By: 

Doug Janzen, President and CEO  
Aequus Pharmaceuticals  
2820-200 Granville Street  
Vancouver, BC CANADA V6C 1S4

  
\_\_\_\_\_  
Witness  
  
\_\_\_\_\_  
Witness

Schedule A

County	Filing Date	Patent	Application No.	Title
USA	August 04, 2016	10,500,196	15/228,382	Transdermal and/or Topical Delivery Systems Composed of Doxylamine Succinate And Pyridoxine Hydrochloride in Combination, Or Alone